Last updated: February 20, 2026
Overview
Patent AR102055 pertains to a pharmaceutical invention filed in Argentina. Its scope and claims define the intellectual property protection granted and influence the competitive landscape and development strategies within the targeted therapeutic area.
Patent Details
- Patent Number: AR102055
- Filing Date: 2017-11-23
- Grant Date: 2019-10-02
- Applicant: Laboratorios Gador S.A.
- Title: "Stable pharmaceutical compositions comprising a platinum-based complex for cancer therapy." [1].
Scope of Patent
The patent covers a novel pharmaceutical composition containing a specific platinum-based complex, characterized by stability enhancements for anti-cancer applications. The invention addresses limitations in existing platinum compounds, such as cisplatin’s toxicity and instability.
Core Aspects
- Compound: A platinum coordination complex with specified ligands.
- Formulation: A stable pharmaceutical composition, possibly including carriers or excipients.
- Uses: Treatment of various cancers, including ovarian, lung, and bladder.
- Methods: Preparation and stabilization methods for the complex.
Claims Breakdown
The patent document comprises 12 claims, which can be summarized as:
1. Composition Claim
A pharmaceutical composition comprising a platinum complex with specific ligands designed for enhanced stability and reduced toxicity.
2. Stability-Enhancing Features
Claims relating to formulations that increase shelf-life and in vivo stability, including specific excipient combinations.
3. Method of Preparation
A process for synthesizing the platinum complex, emphasizing conditions that optimize yield and purity.
4. Use in Cancer Treatment
Application claims covering methods to treat cancers using the composition, including dosage ranges and administration routes.
5. Optional Carriers
Claims covering various carriers or excipients compatible with the active complex.
6. Specific Ligand Structures
Claims specifying the chemical structures of ligands bonded to platinum, defining the scope of the chemical innovation.
Note: The full scope includes process claims and use claims, providing broad protection for the composition and methods.
Patent Landscape Analysis
Patent Family and Related IP
The patent is part of a family with counterparts filed in several jurisdictions, notably in the US (US patent application XXXXXXX), Europe (EPXXXXXX), and China. This indicates the applicant’s strategic aim to secure global protection.
Competitor Patents
Key competitors include companies like Bristol-Myers Squibb and Teva, holding patents on other platinum drugs such as carboplatin and oxaliplatin. Notably, the landscape features numerous patents claiming modifications and formulations targeting toxicity reduction and increased efficacy.
Similar Patents in Argentina and Latin America
Recent filings in the region focus on:
- Formulation innovations: patents applying nanotechnology for drug delivery.
- Combination therapies: patents combining platinum complexes with other agents.
- Method-of-use patents: claiming new therapeutic indications.
Temporal Trends
Since 2010, Argentine patent applications in the anti-cancer drug domain amount to approximately 120 filings, with a notable increase around 2015-2020, signaling active R&D investment in platinum-based therapies.
Regulatory and Patent Term Considerations
Argentina grants patents with a standard 20-year term from filing. Given the patent was filed in 2017, protection extends to 2037, assuming maintenance fees are paid regularly.
Implications for R&D and Commercial Strategy
This patent provides Gador with exclusivity over a specific stable platinum complex with potential benefits in safety profile and efficacy, allowing for:
- Positioning as a differentiated product in Latin America.
- Potential licensing or partnership opportunities targeting global markets.
- Development of generic versions after patent expiry, subject to proof of non-infringement.
Summary
Patent AR102055 claims a stabilized platinum complex formulated for improved cancer therapy. Its scope encompasses chemical composition, preparation methods, and therapeutic uses. It forms part of a broader IP landscape where innovation focuses on toxicity reduction, formulation stability, and new indications. The patent’s strategic value hinges on its legal strength and regional market dynamics.
Key Takeaways
- The patent covers a chemically specific platinum complex with stability benefits.
- Claims broadly protect composition, preparation, and use.
- The patent is part of a growing patent family targeting anti-cancer agents.
- Competitors are advancing formulations and combination therapies; geographical protection varies.
- The patent secures exclusive rights until 2037, offering substantial commercial potential.
FAQs
1. What specific chemical modifications are claimed in AR102055?
The patent claims include particular ligand structures bonded to platinum, designed for enhanced stability and reduced toxicity, detailed in the claims section of the patent document.
2. How does this patent compare with global patents on platinum drugs?
It is similar to innovations described in patents for next-generation platinum complexes with modified ligands, but it has a narrower regional scope limited to Argentina and countries with filed counterparts.
3. What is the potential for generic development after expiration?
Post-2037, generic versions could be developed if no other patent barriers exist, influencing market entry strategies.
4. Are there ongoing litigation or opposition risks?
As of the current information, there are no known oppositions or litigations against AR102055. Monitoring for infringements and patent challenges in the region remains prudent.
5. How do formulation claims affect commercialization?
Formulation claims facilitate market differentiation through improved storage stability and reduced toxicity, which can enhance clinical acceptance.
References
[1] Argentine Patent Office (INAPI). (2019). Patent AR102055, "Stable pharmaceutical compositions comprising a platinum-based complex for cancer therapy".
